Pharmaceutical

Red Light Holland, in Partnership with FDA-Compliant and DEA-Registered Irvine Labs, Updates R&D Plan Focused On Commercialization

Toronto, Ontario--(Newsfile Corp. - January 30, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light…

11 months ago

Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics

ORION CORPORATION PRESS RELEASE 30 JANUARY 2025 at 16.00 EET                   Orion and Invenra announce discovery service and commercial license…

11 months ago

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel…

11 months ago

TOMI Environmental Reports Strong Start to 2025 with January Revenue Growth

FREDERICK, Md., Jan. 30, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in…

11 months ago

Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering…

11 months ago

Rentschler Biopharma announces strategic realignment of its global business operations

LAUPHEIM, Germany, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO)…

11 months ago

Reviva to Participate in the 2025 BIO CEO & Investor Conference

CUPERTINO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage…

11 months ago

Evaxion announces pricing of $10.8 million public offering

COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™…

11 months ago

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Boston (January 30, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to…

11 months ago

Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on…

11 months ago